Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886959 | 1.00 | FDPS (0.50) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL349177 | 0.87 | MAPT (0.50) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL29886954 | 0.87 | MAPT (0.50) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL13192009 | 0.85 | FDPS (0.61) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL30808250 | 0.85 | FDPS (0.61) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL4255761 | 0.84 | FDPS (0.64) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL31160627 | 0.84 | FDPS (0.64) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL25258428 | 0.84 | ALDH1A1 (0.50) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL2850023 | 0.81 | FDPS (0.75) | FDPSALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL31054299 | 0.81 | FDPS (0.75) | FDPSALDH1A1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610258-A1 | FUSED PYRIDAZINE DERIVATIVE | Tenvie Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4375274-A1 | ANNULATED PYRIDAZINE COMPOUND | Nico Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024090469-A1 | FUSED PYRIDAZINE DERIVATIVE | アステラス製薬株式会社 | 2024-05-02 | — | — | WO | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
| CN-117222626-A | Substituted triazine compounds | 安斯泰来制药株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-114981251-B | Dibenzofuran derivative cathepsin K inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
| CN-114981251-A | Diphenyl furan derivative cathepsin K inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021147882-A1 | DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | FDPS 661/4885ALDH1A1 1683/4885SMN1; SMN2 1924/4885 |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | FDPS 283/4885ALDH1A1 1219/4885SMN1; SMN2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.